A photo of Robin Norris.

Robin Norris, MD, MS, MPH


  • Director, Clinical Research for Oncology, Division of Oncology
  • Co-Director, Young Adult Oncology Program, Division of Oncology
  • Associate Professor, UC Department of Pediatrics

About

Locations (2)

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al. Pediatric Blood and Cancer. 2021; 68.

Active and Protected: Developing a "Safer Sex " Handout for Adolescents and Young Adults with Cancer. McGrady, ME; Bredenberg, DL; Danziger-Isakov, L; Rios, J; Frias, O; West, MY; Fisher, P; Salloum, R; Pressey, JG; Norris, RE. Journal of Adolescent and Young Adult Oncology. 2021; 10:351-354.

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Pullarkat, VA; Lacayo, NJ; Jabbour, E; Rubnitz, JE; Bajel, A; Laetsch, TW; Leonard, J; Colace, SI; Khaw, SL; Fleming, SA; et al. Cancer Discovery. 2021; 11:1440-1453.

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Burke, GA A; Beishuizen, A; Bhojwani, D; Burkhardt, B; Minard-Colin, V; Norris, RE; Kabickova, E; Pinarli, FG; Tacyildiz, N; Howes, A; et al. Leukemia. 2020; 34:2271-2275.

Location of Death and End-of-Life Characteristics of Young Adults with Cancer Treated at a Pediatric Hospital. Mark, MS J; Yang, G; Ding, L; Norris, RE; Thienprayoon, R. Journal of Adolescent and Young Adult Oncology. 2019; 8:417-422.

IBRUTINIB + CHEMOIMMUNOTHERAPY (CIT) FOR RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) IN CHILDREN (SPARKLE TRIAL): INITIAL SAFETY, PK, AND EFFICACY. Burke, A; Beishuizen, A; Bhojwani, D; Burkhardt, B; Minard-Colin, V; Norris, R; Kabickova, E; Pinarli, F; Tacyildiz, N; de Jong, J; et al. Hematological Oncology. 2019; 37:57-59.

Pediatric acute lymphoblastic leukemia presenting with periorbital edema. Stein, AP; Norris, RE; Shah, JR. Otolaryngology Case Reports. 2018; 9:11-14.

Collaborating with Adolescents and Young Adults with Cancer as Advisors. McGrady, ME; Norris, RE; Pai, AL H. Journal of Adolescent and Young Adult Oncology. 2018; 7:499-503.

Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Norris, RE; Fox, E; Reid, JM; Ralya, A; Liu, XW; Minard, C; Weigel, BJ. Pediatric Blood and Cancer. 2018; 65.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey